Relationship Between Serum DNA Replication, Clinicopathological Characteristics and Prognosis of Hepatitis B Virus-associated Glomerulonephritis with Severe Proteinuria by Lamivudine Plus Adefovir Dipivoxil Combination Therapy / 生物医学与环境科学（英文）

<p><b>OBJECTIVE</b>To explore the relationship between HBV DNA and the clinical manifestations, pathological types, injury severity, and prognosis with HBV-GN.</p><p><b>METHODS</b>102 patients with HBV-GN were divided into 3 groups, according to the serum titer of the HBV DNA. 24-h urine protein excretion, and other parameters were measured. Renal biopsy were performed. The association between HBV DNA and the pathological stage of membranous nephropathy was analyzed in 78 patients with HBV-MN. 24-h urine protein excretion was used for the evaluation of the prognosis, and the relationship between HBV DNA and prognosis were analyzed.</p><p><b>RESULTS</b>Several findings were demonstrated with the increase of serum HBV DNA: 24-h urine protein excretion, plasma cholesterol, and triglycerides increased significantly (P%lt;0.05), while the plasma level of albumin decreased significantly (P%lt;0.05); The changes of serum creatinine, C3 and C4 were found but no statistical significance. Glomerular deposition of HBVAg increased, and the pathological injury was more severe. The clinical remission rate was lower in the high replication group after treatment as compared with the low replication group (P%lt;0.01).</p><p><b>CONCLUSION</b>With the increase of serum HBV DNA, the urine protein excretion and the kidney injury were more severe, and the clinical remission rate was decreased.</p>

Effect of content of hepatitis B virus DNA in the serum on the pathologic change in hepatitis B virus associated-glomerulonephritis / 中南大学学报(医学版)

OBJECTIVE@#To investigate the correlation between the content of hepatitis B virus DNA(HBV-DNA) in the serum and the pathologic change in hepatitis B virus associated-glomerulonephritis (HBV-GN).@*METHODS@#Forty one HBV-GN patients were divided into 3 groups by the content of HBV-DNA in the serum:low replicate group,midrange replicate group, and high replicate group. The relationship with the content of HBV-DNA in the serum and pathologic stage or change was analyzed in 35 membranous glomerulopathy patients; Effect of the content of hepatitis B virus DNA in the serum on HBVAg deposition in glomeruli of kidney was examined by immunohistochemistry; Effect of HBVAg deposition on pathologic change was observed in membranous glomerulopathy patients.@*RESULTS@#With the multiplication of HBV-DNA in the serum, the pathologic lesion was aggravating from Stage I to Stage III in membranous glomerulopathy patients; the deposition of HBVAg in glomeruli of kidney was increasing; with the increasing of deposition of HBVAg in glomeruli of kidney, the pathologic lesion was aggravating in membranous glomerulopathy patients.@*CONCLUSION@#With the multiplication of HBV-DNA in the serum, the deposition of HBVAg in glomeruli of kidney increases, and the pathologic lesion aggravates, which have significant correlation.

Protective Effect of Riptolide on Renal Tissures in Type 2 Diabetic Rats / 中华高血压杂志

Objective To assess the renal protective effects of triptolide treatment in type 2 diabetic rats and its possible mechanisms.Methods Wistar rats were randomized to receive following approach control (n=7),dia- betic model without treatment (n=7) and diabetic group treated with triptolide[200 ?g/(kg?d),n=7].Plasma glucose (PG),serum creatinine (Scr),total cholesterin (TC),triglyeride (TG),kidney mass (KM),index number of kidney hypertrophy (KM/body mass,KM/BM),and 24 hours urinary albumin (24 h UAL) were determined. The protein expression of monocyte chemoattractant protein-1 (MCP-1),osteopontin (OPN) and ED-1 in renal tissue were determined by immunohistochemical technique.The mRNA expressions of MCP-1 and OPN in kidney tissue were assessed by reverse transcription-polymerase chain reaction (RT-PCR).Results Elevated 24 h UAL was markedly attenuated by triptolide treatment [24 h UAL,triptolide:2.32?0.29 vs diabetic model group:3.89? 0.51 mg/mgCr,P